Vietnamese crab exporterdouble-skinned crabs
Advertisement
Advertisement
TOPIC

Biomedicine: Companies

Related Topics:
Biomedicine: Companies
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
China’s biotech sector has shifted from speed-driven replication to differentiated innovation, according to analysts. Photo: Shutterstock
Biomedicine: Industry Trends

How Chinese biotech is graduating from licensing deals to broader partnerships

InnoCare’s pact with Eli Lilly, potentially worth up to US$3.35 billion, highlights a shift towards bigger partnerships, analysts say.

Hong Kong stock market

‘High tide’ of China biotech deals seen as US curb fears fade: analysts

videocam
Alibaba

Alibaba open-sources AI model that can detect cancer and nearly 150 conditions

Biomedicine: Policy

Biomedicine powerhouse: China targets quarter of global first-in-class drugs

New five-year plan aims to turn the sector into a pillar industry by 2030, driven by breakthroughs in technologies across critical fields.

The plan sets 10 targets, including requiring large pharmaceutical enterprises to generate combined revenue of no less than 3.5 trillion yuan. Photo: Shutterstock
Biomedicine: Industry Trends

ByteDance spin-off Anew Labs raises US$290m amid AI drug design fundraising boom

As AI’s role in drug design advances rapidly, Chinese start-ups are ramping up fundraising efforts.

videocam
Biomedicine: Industry Trends

GSK’s US$750 million cancer drug deal highlights China’s rise as biotech player

The acquisition is the latest in a string of major licensing deals involving Chinese biotechnology firms.

4
Advertisement
Advertisement
Advertisement
Greater Bay Area

Data from Greater Bay Area residents to help improve healthcare policy: GSK

Executive says pharmaceutical company is investing in shared data infrastructure.

GSK’s general manager for Hong Kong and Macau, Nicholas Teo, at the Hong Kong International Biotechnology Conference and Exhibition on Thursday. Photo: Jonathan Wong
IPO

Hong Kong watchdog investigates Cloudbreak Pharma for ‘rigged’ IPO

Regulator cites ‘serious concerns’ about ‘artificial impression of demand’ in US-based company’s US$78 million listing in 2025.

Greater Bay Area

Hong Kong targets biomedicine powerhouse status in debut 5-year plan

Tied to the national strategy, the city’s first five-year blueprint doubles down on Greater Bay Area medical tech and healthcare cooperation.

Technology

As China embraces AI, few US pharmaceutical execs bet on it for innovation

Survey finds drug companies planned to scale AI or had already done so, but few anticipated a ‘wholesale revolution’ from the tech.

videocam
A study of 50 US pharmaceutical company executives found all firms had either fully or partially scaled AI or were planning to. Photo: Shutterstock Images
China’s private sector

China needs monkeys: lab animal shortage could hinder biotech growth

As fundraising and out-licensing deals in China grow, so does demand for monkeys and other primates for testing.

The expansion of China’s biotechnology industry is driving up demand for primates. Photo: Shutterstock
IPO

More Chinese developers of brain-computer interfaces move towards IPOs

Arfysica and Neuracle aim for Star Market listings amid what a Morgan Stanley analyst calls the ‘early stage of a multi-year IPO upcycle’.

videocam
Banking & finance

Why Asian investors are pouring capital into brain tech and surgical robots

Family offices and venture investors across Hong Kong and the wider region are reshaping portfolios to capture long-term biotech growth.

Banking & finance

US surgical robotics firm targets Hong Kong listing to tap mainland China market

Noah Medical expects to file application as early as next year, joining surge of tech listings tapping city’s international fundraising pool.

videocam
Noah Medical has begun preparations for a Hong Kong listing. Photo: Handout
Artificial intelligence

Biomedicine | China thinks big on brain-computer interfaces

Launch of commercial BCI implantation, ahead of US, offers hope to millions with brain or spinal injuries as plans are made for the technology’s wider use.

China thinks big on brain-computer interfaces after world-first surgery
Hong Kong stock market

China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial

The biliary tract cancer trial is the latest breakthrough for Akeso’s ivonescimab, which has also shown promise in treating some lung cancers.

Hong Kong stock market

China rushes to develop Moderna-style cancer vaccines amid market frenzy

Chinese biotech firms are already working on more than 100 cancer vaccines. Now, many are seeing their shares surge amid Moderna’s breakthrough.

videocam
7
Advertisement
Advertisement
Advertisement
Wuxi Biologics

WuXi Biologics posts 4.3% rise in first-half profit, defying biotech headwinds

Higher gross margins, surging projects and continued demand from North American markets help power the drug developer’s strong first-half performance.

Wuxi Biologics is a pharmaceutical research and services company based in Wuxi, Jiangsu province, China. Photo: Shutterstock
Medicine

Overseas licensing has helped fuel China’s biotech profits. Will it last?

Out-licensing deals have overtaken IPOs as the primary lifeline for cash-starved Chinese drug makers, analysts say.

videocam
Hong Kong economy

Chinese tech, pharma firms eye Hong Kong as springboard for global expansion

Industry leaders highlight city’s international reach and expertise as state-owned drug maker considers Northern Metropolis project investment.

Science

Chinese stem cell therapy restores heart function in 90% of trial patients

Study finds patients injected with iPSC-derived heart muscle cells outperform control group on cardiac function tests after bypass surgery.

videocam
12
Patients with severe heart failure may experience shortness of breath after walking just a few steps, the inability to lie flat and sleep at night, and frequent hospital visits. Photo: Shutterstock
Biomedicine: Industry Trends

Patience needed before human gene therapy trials, Stanford expert says

Human testing could take up to five years to ramp up, but AI approaches will yield results in time, Karoly Nikolich says.

videocam
Karoly Nikolich, pictured at the Hong Kong Convention and Exhibition Centre on August 8. Photo: Edmond So
Science

Chinese ‘yeast factory’ boosts cancer drug production by 1,000 times

Turning point comes from cross-disciplinary collaboration, including across plant biochemistry, synthetic biology and protein engineering.

videocam
China’s private sector

China’s drug firms set to compete on the world stage, analysts say

Amid systemic efficiency and a wave of innovation, the country’s biotech sector is expanding at a pace that has caught the market off guard.

4
China technology

China races to develop brain-computer interfaces that can be inserted in minutes

The technology – which allows patients to control digital devices using their thoughts – can be implanted like a stent in just a few minutes.

Chinese start-ups are developing brain-computer interfaces that can be implanted via a vein in just 10 minutes. Photo: Shutterstock
China’s private sector

Global pharma giants turn to Chinese biotech to tap innovation, valuation growth

The foreign investments can help Chinese companies grow and compete on the global stage, according to Citic Securities.

Test tubes are arranged in front of an AstraZeneca logo in this illustration picture taken May 21, 2021. Photo: Reuters
China’s private sector

Sugar for the pill: US$8b fund boosts Hong Kong’s biotech hub ambitions

Hong Kong Investment Corporation is stepping up its efforts to position itself amid Beijing’s challenge to US pharmaceutical dominance.

Banking & finance

China biotech giant WuXi AppTec sees first-half earnings surge amid US scrutiny

Strong orders for weight-loss and diabetes treatments drive firm’s growth, despite being caught up in US efforts to curb China’s ambitions.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement